AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01222299
Drug: bepotastine besilate nasal product - medium dose
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile nasal product
Trial: NCT01222299
Drug: bepotastine besilate nasal product - high dose
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile nasal product
Trial: NCT02861261
Drug: 1. Berberine placebo tablets; 2. Probiotics placebo powder
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Trial: NCT03794778
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175 mg/m2, i.v.,d1; once every 21days
Trial: NCT03794778
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC 5, i.v.,d1; once every 21days,
Trial: NCT04471987
Drug: IL12-L19L19
RxNorm normalized name: Immunocytokine NHS-IL12
DrugBank: Immunocytokine NHS-IL12 (DB17585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.
Trial: NCT04471987
Drug: IL12-L19L19
RxNorm normalized name: Immunocytokine NHS-IL12
DrugBank: Immunocytokine NHS-IL12 (DB17585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
Trial: NCT01868477
Drug: Deferasirox DFX, DT
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: provided as dispersible tablets for oral use in 125 and 250, 500 mg
Trial: NCT01868477
Drug: Erythropoietin alpha
RxNorm normalized name: alpha tocopherol
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01868477
Drug: Deferasirox DFX, FCT
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
Trial: NCT00562965
Drug: inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
Trial: NCT00562965
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
Trial: NCT00562965
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous rituximab at a dose of 375 mg/m2 on day 1
Trial: NCT00562965
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
Trial: NCT00562965
Drug: prednisone/prednisolone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
Trial: NCT00562965
Drug: mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitoxantrone 10 mg/m2 intravenous on day 2
Trial: NCT00562965
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 25 mg/m2 intravenous on days 2 through 4
Trial: NCT00562965
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dexamethasone 20 mg/day on days 1-5
Trial: NCT01972711
Drug: SEP-363856
RxNorm normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-36385625 as a single oral dose of 50 mg
Trial: NCT00847093
Drug: LMX4
RxNorm normalized name: LIDOCAINE 40 mg in 1 g TOPICAL CREAM [LMX4]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One inch every six hours
Trial: NCT01972711
Drug: Amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amisulpride as a single oral dose of 400 mg
Trial: NCT00031551
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02554175
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol was administered to achieve target propofol Ce
Trial: NCT02530541
Drug: CHG
RxNorm normalized name: CHGN111
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varied application times
Trial: NCT04224116
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
Trial: NCT01354925
Drug: Insulin treatment during Ramadan
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
Trial: NCT04224116
Drug: SSI
RxNorm normalized name: Tussin
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Salin isotonic injected
Trial: NCT00004233
Drug: triacetyluridine
RxNorm normalized name: Triacetyluridine
DrugBank: Uridine triacetate (DB09144)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01422226
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
Trial: NCT03487874
Drug: 0.75% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Trial: NCT04887961
Drug: PLD and Trabectedin rechallenge
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
Trial: NCT00492011
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
Trial: NCT00264680
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00264680
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02369523
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
Trial: NCT02369523
Drug: Ropivacaine cocktail (PIC)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
Trial: NCT02369523
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine
Trial: NCT02700685
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard pharmaceutical treatment for ADHD, slow release.
Trial: NCT00492011
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
Trial: NCT00492011
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
Trial: NCT01178788
Drug: 17 alpha-hydroxy progesterone caproate
RxNorm normalized name: 17-alpha-hydroxy-progesterone caproate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly injection of 17 P
Trial: NCT01178788
Drug: micronized Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: daily administration of vaginal progesterone
Trial: NCT00416273
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
Trial: NCT00846365
Drug: Olmesartan medoxomil-hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide/Olmesartan Medoxomil 25 MG-40 MG Oral Tablet [OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE]
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Trial: NCT02754258
Drug: MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 days on oral methylphenidate administered 2 times daily before lunch and supper.
Trial: NCT01026415
Drug: brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 mg/kg IV every 21 days
Trial: NCT01026415
Drug: rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day PO
Trial: NCT01026415
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg IV
Trial: NCT01026415
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg/day PO
Trial: NCT01026415
Drug: brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.2 mg/kg IV every 21 days
Trial: NCT01806415
Drug: Fenobam
RxNorm normalized name: Fenobam
DrugBank: Fenobam (DB12931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
Trial: NCT02300311
Drug: nonivamide + nicoboxil (Finalgon cream)
RxNorm normalized name: nicoboxil
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
Trial: NCT02300311
Drug: placebo matching nonivamide + nicoboxil (Finalgon cream)
RxNorm normalized name: nicoboxil
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
Trial: NCT03279133
Drug: Ledipasvir 90mg/Sofosubvir 400mg
DrugBank: Ledipasvir (DB09027)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
Trial: NCT00825617
Drug: Hormone replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
Trial: NCT01124617
Drug: Tapentadol
RxNorm normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
Trial: NCT04567290
Drug: Chewed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
Trial: NCT04567290
Drug: Swallowed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
Trial: NCT04260113
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib orally 500mg once daily half an hour after meal
Trial: NCT00392106
Drug: propafenone
RxNorm normalized name: Propafenone
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
Trial: NCT00392106
Drug: flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
Trial: NCT00392106
Drug: dofetilide
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
Trial: NCT00392106
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
Trial: NCT02577029
Drug: ARC-520
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
Trial: NCT02577029
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg once daily; oral
Trial: NCT02577029
Drug: tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg once daily; oral
Trial: NCT02577029
Drug: antihistamine
RxNorm normalized name: Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
Trial: NCT02078817
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
Trial: NCT00226200
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02734368
Drug: Hyperpolarized Helium-3
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04063839
Drug: Elbasvir / Grazoprevir Oral Tablet
RxNorm normalized name: elbasvir / grazoprevir Oral Tablet
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCV treatment according to Norwegian guidelines
Trial: NCT00194857
Drug: erythropoietin, GCSF
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02594163
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02594163
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02594163
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00575029
Drug: megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg by mouth daily
Trial: NCT01653743
Drug: urinary hCG (u-hCG)
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
Trial: NCT01653743
Drug: Follitropin alpha
RxNorm normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
Trial: NCT01210053
Drug: malate Given orally
RxNorm normalized name: malate
DrugBank: Malate Like Intermediate (DB03343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
Trial: NCT00448409
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
Trial: NCT01980654
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive 560 mg of Ibrutinib orally.
Trial: NCT01980654
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive rituximab 375 mg/m2 intravenously
Trial: NCT02133053
Drug: Beclomethasone
RxNorm normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone nasal spray
Trial: NCT00265434
Drug: Pulmozyme
RxNorm normalized name: Pulmozyme
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04765787
Drug: Combination of Paracetamol 650mg + Orphenadrine 50mg
RxNorm normalized name: orphenadrine, combinations
DrugBank: Orphenadrine (DB01173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
Trial: NCT02225418
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02225418
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03704298
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT03427892
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
Trial: NCT04023721
Drug: Inarigivir soproxil
RxNorm normalized name: Inarigivir soproxil
DrugBank: Inarigivir soproxil (DB15063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir soproxil 200 mg tablets